Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Ou connectez-vous avec votre réseau social favori

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

ISQUAEMIA BIOTECH, S.L.

ISQUAEMIA BIOTECH, S.L._logo
4
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Isquaemia is a Biotech company that develops a new line of drugs and compounds for treatments of Central Nervous System (CNS) pathologies. Isquaemia is developing a new drug for the treatment of stroke.

MADRID, MADRID, Spain

Send a message

Anglais

ISQUAEMIA BIOTECH, S.L.

Anglais

Isquaemia Biotech is a Biotech Company focused on development of a new line of drugs and compounds to treat the Central Nervous System (CNS) pathologies, such as Acute Ischemic Stroke (AIS).

Isquaemia is developing a new neuroprotective drug for the treatment of AIS that seeks to improve the efficacy of current treatments, the therapeutic window and meet the clinical needs not covered. The drug acts in a specific area of ​​the...

See more

Isquaemia Biotech is a Biotech Company focused on development of a new line of drugs and compounds to treat the Central Nervous System (CNS) pathologies, such as Acute Ischemic Stroke (AIS).

Isquaemia is developing a new neuroprotective drug for the treatment of AIS that seeks to improve the efficacy of current treatments, the therapeutic window and meet the clinical needs not covered. The drug acts in a specific area of ​​the brain and it is able to reduce and even reverse the neurological damage caused.

The new drug is a hybrid steroid-nitrone, with neuroprotective and neurorepairer characteristics, that can reduce and reverse the neurological damage caused after the stroke.

The drug under development is in the preclinical phase, where tests on toxicology and metabolism have already been successfully overcome in animal models (mice and rats). To date, the results obtained with the candidate drugs of Isquaemia are totally positive. If we compare the results of our candidates and those obtained with other drugs on the market, we find that Isquaemia's products outperform them in terms of neuroprotection, permeability, neurorepair and improvement of clinical conditions.

Currently, the Isquaemia's drug is starting the regulatory preclinical phase.

The new Isquaemia drug will have a good position in the current market due to the absence of competitors (therapeutic alternatives) in neuroprotection.

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1012 Entities

Communities